Compound information
- Natural Products
- NACP10030
- Molecular Formula
- C19H16O9
- Molecular Weight
- 388.079432092 g/mol
- Structure
-
- IUPAC Name
- 2-(5-hydroxy-3,7-dimethoxy-4-oxo-chromen-2-yl)-3,5-dimethoxy-1,4-benzoquinone
- InChI
- InChI=1S/C19H16O9/c1-24-8-5-9(20)13-11(6-8)28-18(19(27-4)16(13)23)14-10(21)7-12(25-2)15(22)17(14)26-3/h5-7,20H,1-4H3
- InChI Key
- BJZZOVMHOUHQCF-UHFFFAOYSA-N
- SMILES
- O=C1C=C(OC)C(=O)C(OC)=C1C=2OC=3C=C(OC)C=C(O)C3C(=O)C2OC
- CAS
- SuperClass
- Organoheterocyclic compounds
- Class
- Benzopyrans
- SubClass
- 1-benzopyrans
- Source
- CNP0259413
Warheads
- Michael Acceptor
-
ADMET Property
Physicochemical Property
| Property | Value | Property | Value |
|---|---|---|---|
| Heavy Atom Count | 28 | Ring Count | 3 |
| Heteroatom Count | 9 | Rotatable Bond Count | 5 |
| Hydrogen Bond Acceptor Count | 9 | Hydrogen Bond Donor Count | 1 |
| Topological Polar Surface Area | 121.5 Å2 | LogP | 1.862 |
| LogS | -4.645 | LogD | 2.282 |
Absorption
| Property | Value | Property | Value |
|---|---|---|---|
| Pgp inhibitor | 0.925 | Pgp substrate | 0.003 |
| HIA | 0.96 | F20 % | 0.001 |
| F30 % | 0.0 | Caco-2 | -5.329 |
| MDCK | -4.629 |
Distribution
| Property | Value | Property | Value |
|---|---|---|---|
| BBB Penetration | 0.0 | PPB | 96.015 |
| VD | 0.886 | Fu | 1.205 |
Metabolism
| Property | Value | Property | Value |
|---|---|---|---|
| CYP1A2 inhibitor | 0.996 | CYP1A2 substrate | 0.4 |
| CYP2A6 substrate | 0.403 | CYP2B6 substrate | 0.296 |
| CYP2C19 inhibitor | 0.612 | CYP2C19 substrate | 0.803 |
| CYP2C8 substrate | 0.335 | CYP2C9 inhibitor | 0.538 |
| CYP2C9 substrate | 0.029 | CYP2D6 inhibitor | 0.409 |
| CYP2D6 substrate | 0.127 | CYP2E1 substrate | 0.258 |
| CYP3A4 inhibitor | 0.858 | CYP3A4 substrate | 0.089 |
Excretion
| Property | Value | Property | Value |
|---|---|---|---|
| T1/2 | 0.666 | CL | 4.732 |
Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| hERG Blockers | 0.002 | Hepatotoxicity | 0.614 |
| Mutagenicity | 0.247 | Rat Oral Acute Toxicity | 0.1 |
| FDAMDD | 0.329 | Skin Sensitization | 0.958 |
| Carcinogenicity | 0.267 | Eye Corrosion | 0.004 |
| Eye Irritation | 0.06 | Respiratory Toxicity | 0.137 |
Environmental Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| Bioconcentration Factors | 1.322 | IGC50 | 5.094 |
| LC50FM | 5.693 | LC50DM | 5.764 |
Tox21 Pathway
| Property | Value | Property | Value |
|---|---|---|---|
| NR-AR | 0.498 | NR-AR-LBD | 0.741 |
| NR-AhR | 0.74 | NR-Aromatase | 0.47 |
| NR-ER | 0.475 | NR-ER-LBD | 0.536 |
| NR-PPAR-gamma | 0.846 | SR-ARE | 0.844 |
| SR-ATAD5 | 0.758 | SR-HSE | 0.283 |
| SR-MMP | 0.973 | SR-p53 | 0.934 |
Similar covalent inhibitors
No similar covalent inhibitors found for this compound.
Similar covalent drugs
No similar covalent drugs found for this compound.